Researcher tests first-in-class compound for neuroprotection with hope of stopping MS disease progression
PUBLIC RELEASE DATE: 20-Nov-2013
Contact: Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Researcher tests first-in-class compound for neuroprotection with hope of stopping MS disease progression
Mount Sinai's Patrizia Casaccia, M.D., partners with Karyopharm Therapeutics to speed new drug development
A $500,000 drug development grant from the National Multiple Sclerosis Society (NMSS) was awarded to a partnership be